PharmaResearch secures a patent for intra-articular injection material from the world’s top 5 patent offices

It aims to alleviate joint pain and establish a foothold in the global intra-articular market.

PharmaResearch, led by CEO Kim Thinkyou and Kang Ki-seok, has acquired a patent for intra-atyicular treatment material "NPNP-001" in Europe and China, thus securing patent rights from the top 5 patent offices in the IP5 countries (USA, Europe, Japan, China, and Korea).

"NPNP-001" is a intra-articular injection material containing nucleic acid and chitosan, which improves the retention and lubricating effect in joint synovial fluid. Moreover, it has viscosity and elasticity similar to human synovial fluid, which helps reduce pain caused by repetitive shocks for a long time.

PharmaResearch official said, "We have secured a stable entry into the global intra-articular market by securing patent rights in all IP5 countries based on our unique technological capabilities. NPNP-001 is being developed as a next-generation CONJURAN product, and we expect it to be an innovative medical device that will protect knee health worldwide."

PharmaResearch is a regenerative medicine-based pharmaceutical and bio company that produces and sells pharmaceuticals, medical devices, cosmetics, and health-functional foods centered around tissue restoration materials such as DOT™ PDRN and DOT™ PN. Its representative products include REJURAN®, CONJURAN®, REJURAN Cosmetics, RE-AN®, eye drops, and REJUDERMA®.